My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 134

    1.

    Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays.

    Tennant RW.

    Environ Health Perspect. 1998 Apr;106 Suppl 2:473-6.PMID: 9599694 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.

    Battershill JM, Fielder RJ.

    Hum Exp Toxicol. 1998 Apr;17(4):193-205. Review.PMID: 9617631 [PubMed - indexed for MEDLINE]Related articles

    3.

    Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens.

    Tennant RW, Spalding J, French JE.

    Mutat Res. 1996 Sep;365(1-3):119-27. Review.PMID: 8898993 [PubMed - indexed for MEDLINE]Related articles

    4.

    A perspective on current and future uses of alternative models for carcinogenicity testing.

    Goodman JI.

    Toxicol Pathol. 2001;29 Suppl:173-6. Review.PMID: 11695554 [PubMed - indexed for MEDLINE]Related articles

    5.

    Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.

    Spalding JW, French JE, Tice RR, Furedi-Machacek M, Haseman JK, Tennant RW.

    Toxicol Sci. 1999 Jun;49(2):241-54.PMID: 10416269 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Alternative models for carcinogenicity testing: weight of evidence evaluations across models.

    Cohen SM.

    Toxicol Pathol. 2001;29 Suppl:183-90. Review.PMID: 11695556 [PubMed - indexed for MEDLINE]Related articles

    7.

    Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?

    Gaylor DW.

    Regul Toxicol Pharmacol. 2005 Mar;41(2):128-33. Epub 2004 Dec 19.PMID: 15698536 [PubMed - indexed for MEDLINE]Related articles

    8.

    Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays.

    Spalding JW, French JE, Stasiewicz S, Furedi-Machacek M, Conner F, Tice RR, Tennant RW.

    Toxicol Sci. 2000 Feb;53(2):213-23.PMID: 10696769 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.

    Contrera JF, DeGeorge JJ.

    Environ Health Perspect. 1998 Feb;106 Suppl 1:71-80. Review.PMID: 9539006 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models.

    Tennant RW, French JE, Spalding JW.

    Environ Health Perspect. 1995 Oct;103(10):942-50.PMID: 8529591 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions.

    Sistare FD, Thompson KL, Honchel R, DeGeorge J.

    Int J Toxicol. 2002 Jan-Feb;21(1):65-79. Review.PMID: 11936901 [PubMed - indexed for MEDLINE]Related articles

    12.

    Expectations for transgenic rodent cancer bioassay models.

    Ashby J.

    Toxicol Pathol. 2001;29 Suppl:177-82. Review.PMID: 11695555 [PubMed - indexed for MEDLINE]Related articles

    13.

    The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.

    Tennant RW, Stasiewicz S, Eastin WC, Mennear JH, Spalding JW.

    Toxicol Pathol. 2001;29 Suppl:51-9. Review.PMID: 11695562 [PubMed - indexed for MEDLINE]Related articles

    14.

    Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.

    Yamamoto S, Urano K, Koizumi H, Wakana S, Hioki K, Mitsumori K, Kurokawa Y, Hayashi Y, Nomura T.

    Environ Health Perspect. 1998 Feb;106 Suppl 1:57-69. Review.PMID: 9539005 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.

    Yamamoto S, Urano K, Nomura T.

    Toxicol Lett. 1998 Dec 28;102-103:473-8. Review.PMID: 10022298 [PubMed - indexed for MEDLINE]Related articles

    16.

    The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies--implications for REACH.

    Wells MY, Williams ES.

    Regul Toxicol Pharmacol. 2009 Mar;53(2):150-5. Epub 2008 Dec 25.PMID: 19126422 [PubMed - indexed for MEDLINE]Related articles

    17.

    The role of transgenic mouse models in carcinogen identification.

    Pritchard JB, French JE, Davis BJ, Haseman JK.

    Environ Health Perspect. 2003 Apr;111(4):444-54. Review.PMID: 12676597 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Animal carcinogenicity studies: 3. Alternatives to the bioassay.

    Knight A, Bailey J, Balcombe J.

    Altern Lab Anim. 2006 Feb;34(1):39-48.PMID: 16522149 [PubMed - indexed for MEDLINE]Related articles

    19.

    P53+/- hemizygous knockout mouse: overview of available data.

    Storer RD, French JE, Haseman J, Hajian G, LeGrand EK, Long GG, Mixson LA, Ochoa R, Sagartz JE, Soper KA.

    Toxicol Pathol. 2001;29 Suppl:30-50. Review.PMID: 11695560 [PubMed - indexed for MEDLINE]Related articles

    20.

    Alternative models for carcinogenicity testing.

    Cohen SM, Robinson D, MacDonald J.

    Toxicol Sci. 2001 Nov;64(1):14-9.PMID: 11606797 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity